US FDA accepts MS drug Lemtrada resubmission for review
US FDA accepts MS drug Lemtrada resubmission for review
The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1838 Views
-
Last post by frodo
-
- 0 Replies
- 1179 Views
-
Last post by NHE
-
- 0 Replies
- 1669 Views
-
Last post by frodo
-
- 0 Replies
- 1204 Views
-
Last post by frodo
-
- 1 Replies
- 1673 Views
-
Last post by frodo
-
- 0 Replies
- 1970 Views
-
Last post by NHE
-
- 0 Replies
- 2225 Views
-
Last post by NHE
-
- 0 Replies
- 1051 Views
-
Last post by frodo
-
- 1 Replies
- 1370 Views
-
Last post by NHE